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ABSTRACT
Objectives: The Acne Priority Setting Partnership
(PSP) was set up to identify and rank treatment
uncertainties by bringing together people with acne,
and professionals providing care within and beyond the
National Health Service (NHS).
Setting: The UK with international participation.
Participants: Teenagers and adults with acne,
parents, partners, nurses, clinicians, pharmacists,
private practitioners.
Methods: Treatment uncertainties were collected via
separate online harvesting surveys, embedded within the
PSP website, for patients and professionals. A wide
variety of approaches were used to promote the surveys
to stakeholder groups with a particular emphasis on
teenagers and young adults. Survey submissions were
collated using keywords and verified as uncertainties by
appraising existing evidence. The 30 most popular
themes were ranked via weighted scores from an online
vote. At a priority setting workshop, patients and
professionals discussed the 18 highest-scoring questions
from the vote, and reached consensus on the top 10.
Results: In the harvesting survey, 2310 people,
including 652 professionals and 1456 patients (58%
aged 24 y or younger), made submissions containing at
least one research question. After checking for relevance
and rephrasing, a total of 6255 questions were collated
into themes. Valid votes ranking the 30 most common
themes were obtained from 2807 participants. The top 10
uncertainties prioritised at the workshop were largely
focused on management strategies, optimum use of
common prescription medications and the role of non-
drug based interventions. More female than male patients
took part in the harvesting surveys and vote. A wider
range of uncertainties were provided by patients
compared to professionals.
Conclusions: Engaging teenagers and young adults in
priority setting is achievable using a variety of
promotional methods. The top 10 uncertainties reveal an
extensive knowledge gap about widely used interventions
and the relative merits of drug versus non-drug based
treatments in acne management.
INTRODUCTION
During the last decade, the inclusive methods
pioneered and validated by the James Lind
Alliance ( JLA) for treatment-related research
priority setting have become well established
in the UK (http://www.jla.nihr.ac.uk). JLA
Priority Setting Partnership (PSPs) bring
together, on a level playing ﬁeld, people with a
disease and those who treat them, ﬁrst to iden-
tify, and then to prioritise, unanswered ques-
tions (uncertainties) about existing
treatments. Twenty-six PSPs have been com-
pleted to date, including this and a further
three on diseases of the skin.1–3 Conditions
covered include those primarily affecting the
elderly (eg, dementia and stroke), infants and
young children (cleft lip and palate, eczema)
or people at any time of life (Lyme disease,
asthma). So far, no PSP has targeted a disease
with peak prevalence during adolescence in
mainly healthy subjects. Although acne is start-
ing earlier4 and lasting longer,5–7 possibly as a
result of lifestyle changes, peak prevalence is
between the ages of 16 and 20 years.8 9 The
age range of acne now spans ﬁve decades; few
Strengths and limitations of this study
▪ This study has demonstrated that teenagers and
young adults can be engaged in priority setting,
but considerable resources went into promo-
tional activities that were subsequently found to
be ineffective.
▪ To ensure all views were captured, much effort
went into collecting responses from a wide spec-
trum of people with acne and different types of
care professionals; despite this, males with acne
were under-represented.
▪ The volume of unsorted questions was so large
that grouping into broad themes was the only
way of generating manageable numbers to take
to the prioritisation stages without overwhelming
participants.
▪ Saturation was reached in that no new uncertain-
ties were contained within the final submissions
to the harvesting survey.
▪ Methods were developed for sorting and sharing
large volumes of submissions.
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teenagers in Westernised societies are able to avoid acne in
one form or other.10 For reasons that remain poorly
understood, postadolescent acne is more common in
women than in men.5–7 Acne was one of three skin condi-
tions in the top 10 most prevalent diseases worldwide in
2010.11 However, the most widely used treatments have
changed little in the past 30 years. Systematic reviews have
consistently shown a paucity of robust evidence from
adequately powered randomised controlled trials.12 13
When compared with disease burden as estimated by
disability-adjusted life years from the Global Burden of
Disease 2010 project, acne is under-represented in the
Cochrane Database of Systematic Reviews.14
Most clinical trials of new and existing therapies in
acne have been conducted by the pharmaceutical indus-
try; few independent trials are conducted anywhere in
the world. In consequence, key issues of importance to
patients and clinicians remain to be adequately investi-
gated and addressed.
The Acne PSP was formally initiated in November
2012. In order to collect a representative range of opi-
nions, we sought to involve not only National Health
Service (NHS) patients and staff but also the large
numbers of people with acne who never present to a
doctor.15–19 Of importance, we considered that a success-
ful priority setting exercise, by highlighting signiﬁcant
evidence gaps, would stimulate new high quality
treatment-related research within and beyond the UK.
METHODS
A steering group to oversee the PSP was established in
accordance with JLA guidelines and held its ﬁrst meeting
in January 2013. The steering group, which was chaired
by a representative of the JLA, consisted of people with
acne, and healthcare and allied professionals involved in
treatment delivery, as well as experts in patient and public
involvement in research and information management.
At the initial meeting, the protocol and terms of refer-
ence for the steering group were formally adopted. The
protocol was developed with reference to the JLA guide-
book with modiﬁcations necessitated by targeting a pre-
dominantly adolescent population.
Stage 1: set-up
Organisations that represent people who treat acne in
any setting were contacted and invited to become part-
ners. In the UK, there is no longer a patient group
representing people with acne. However, we invited
VERITY, the support group for women with polycystic
ovarian syndrome, to become a partner as persistent
acne is often a feature of this condition. Organisations
that volunteered to help deliver the priority setting exer-
cise were also invited to become partners. Partner orga-
nisations were expected to help promote the PSP to
their members or to the public and encourage participa-
tion in the harvesting survey and vote. They were
required to afﬁliate to the JLA. Our partners are listed
in the Acknowledgements section.
As the target population was expected to comprise
mainly of teenagers and young adults, it was decided
that a dedicated website should be used to collect and
disseminate information. The website was launched in
April 2013 and included background information about
the PSP, partners and steering group members, with a
brief summary of acne treatments and ways of obtaining
them.
In order to better understand what would motivate
people to take part in the harvesting survey, an informal
meeting was held in February 2013 in Harrogate, to
which approximately equal numbers of people with
acne, and healthcare professionals, were invited together
with two dermatology patients without acne but with
marketing experience. Attendees reviewed and changed
the publicity ﬂyer and harvesting survey, which had been
drafted to closely match the traditional open JLA layout.
To make the harvesting survey form more visually attract-
ive and clearer for young people, two versions were
produced. The patient version was more structured,
including images and speciﬁc questions about each
treatment type, and contained additional questions to
capture details about current and past sources of profes-
sional help and treatment. The professional version of
the survey adhered to a more conventional layout with a
limit of ﬁve questions per respondent. Publicity materi-
als were simple in design, carried the banner “Join the
ﬁght against acne” to reﬂect the campaigning dimension
requested by meeting participants, and included a QR
code linking directly to the survey. To increase participa-
tion by teenagers and young adults, a small ﬁnancial
incentive was offered to respondents to the patients’
version. This was £25 or local currency equivalent in vou-
chers for a global online retailer, awarded to 50 people
who submitted at least one uncertainty and whose
names were selected at random at the close of the
survey. No ﬁnancial incentive to take part was offered to
the professionals.
Stage 2: harvesting uncertainties
Both versions of the survey to collect treatment uncer-
tainties were constructed in Survey Monkey and embed-
ded into the PSP website. The survey was open between
the 22 May and 31 August 2013. It was kept open longer
than the planned 8 weeks after analyses of demographic
data showed low levels of participation by some target
groups.
A variety of traditional as well as novel methods were
utilised to publicise the survey. Organisational stake-
holders were asked to promote the PSP and survey to
members via email, via their own web site or in any
other way they wished. Posters and ﬂyers were sent to
local and specialist centres within the UK. In addition, a
national chain of community pharmacies distributed
ﬂyers via their branches. A dedicated Twitter account
was set up and at least one original tweet per day was
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issued until the ﬁnal workshop had been completed.
Steering group members were asked to email colleagues
and contacts and/or put adverts in local newsletters.
Two national health-related organisations, Talk Health
and Embarrassing Bodies, promoted the survey via a
variety of mechanisms including their own web sites.
A celebrity agreed to endorse the PSP on the home
page of the web site and another generated a promo-
tional video. The local National Institute of Health
Research network (North East Yorkshire and North
Lincolnshire) took the lead in disseminating informa-
tion to colleagues in other networks, including Primary
Care Research Networks, and also approached local edu-
cational establishments and NHS trusts.
To complement the harvesting survey, a search of
research recommendations within recent, relevant and
reliable systematic reviews or treatment guidelines, was
undertaken with a view to including any novel uncertain-
ties within the prioritisation exercise.
Stage 3: processing the uncertainties
The survey generated very many responses, so consider-
ation was required of the most efﬁcient mechanism for
analysing the data and distributing workload across the
project team. Submissions from Survey Monkey were
downloaded into Microsoft Excel to facilitate reﬁning
and collating uncertainties. Submitted text was often
rephrased for clarity and to separate out individual
questions.
To maximise ﬂexibility and to enable the data to be
sliced in various ways, controlled vocabulary terms were
assigned to the uncertainties. First, uncertainties were
collated into themes, many of which were necessarily
broad (covering aspects such as adverse effects, long-
term management and skin care). The themes were sup-
plemented with terms relating to relevant intervention
categories (eg, phototherapy, antibiotics and topical
therapies). These controlled lists were deﬁned using the
clinical expertise within the Steering Group. The key
concepts were then indexed by assigning National
Library of Medicine Medical Subject Headings (MeSH),
commonly used in searching literature, to each of the
included uncertainties. Not all concepts were available
in the MeSH vocabulary. To identify controlled terms for
these omitted concepts, the Excel ﬁle was loaded into
Google Sheets and parsed with the ISA-TAB Ontomaton
tool.20 As a result, the medical subject headings were
extended to include terms from other vocabularies such
as Clinical Terms V.3 (Read Codes; National Health
Service National Coding and Classiﬁcation Centre).
Most of the data were validated on input to minimise
typographical errors and ensure consistency across the
subsets of data; the exception being one of the MeSH
descriptor ﬁelds that enabled more obscure concepts to
be included. There was no limit to the number of key
words that could be assigned to any uncertainty.
Therefore, each uncertainty could be indexed to a high
level of detail if needed, facilitating segmentation of the
data and enabling similar submissions to be merged.
In order to manage the above process and the distri-
bution of the data across the project team, the datasets
were stored in a central online document repository.
Initially based on the National Institute for Health
Research (NIHR) SharePoint portal, the ﬁles were later
transferred to a dedicated site on the NIHR Hub when
the NIHR moved its infrastructure onto the Google plat-
form. The list of uncertainties generated by this process
was reviewed at a meeting of the Steering Group to
decide which to take forward to the ranking stage. The
group was provided with information on the number of
related submissions so that the shortlist was decided
largely by popularity of the uncertainty.
As a ﬁnal check, the International Clinical Trials
Registry (http://apps.who.int/trialsearch/) and the
Database of Abstracts of Reviews of Effects (DARE) were
searched to ensure that no uncertainty was already
being addressed by an ongoing clinical study or had
been the subject of an existing or planned high quality
systematic review.
Stage 4: voting and ranking
Because large numbers of young people were expected
to take part in the vote, the number of questions on the
shortlist was limited to 30. As in the harvesting survey,
the voting form was constructed in Survey Monkey and
embedded in the PSP web site. Each respondent was
asked to choose the three questions they felt were most
important and to rank them. The order of questions on
the voting form was random. The vote was open from 22
December 2013 to 10 February 2014. The same methods
used to promote the harvesting survey were used to
promote the vote.
A weighted ranking system was used to generate scores
from the vote; the ﬁrst choice question scored three
points, second choice two points and third choice one
point. Summed scores from patients and professionals
were calculated separately; summed scores from profes-
sionals were adjusted to take account of the lower
number who voted, so that ranks could be validly com-
pared from both groups. Votes from respondents who
identiﬁed themselves as researchers or ‘other’ were
excluded. The Steering Group appraised the ranked
scores from patients and professionals and selected 18
uncertainties to take forward to the priority setting work-
shop based on the highest ranking by both groups.
Stage 5: priority setting workshop
The ﬁnal stage of the PSP was the workshop. This was
held at the London headquarters of the British
Association of Dermatologists (BAD), on 04 March 2014.
Equal numbers of people with acne and healthcare pro-
fessionals working within and outside the NHS were
invited to attend. Representatives of partner organisa-
tions and Steering Group members not regularly
involved in patient care attended as observers. To make
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informed decisions, participants were provided with
ranks from the vote and the number of related submis-
sions from the harvesting survey.
Sample size and composition
Sample sizes were available from two previously com-
pleted PSPs on eczema and vitiligo; 493 and 461 partici-
pants, respectively, submitted uncertainties to each PSP.
Since acne is a more common condition, the protocol
for the Acne PSP set an aspiration of 600 respondents
for the harvesting survey. While no formal target was set
for the vote, numbers and sample composition were
closely monitored so that the voting period could be
extended if necessary. For both the harvesting survey
and the vote, considerable efforts were made to collect
responses from representative samples of people with
acne and the professionals who care for them. To assist
with this, extensive demographic information was col-
lected for the survey and the vote.
RESULTS
Harvesting and collating uncertainties
A total of 4363 people submitted the harvesting survey
form. However, many patients and professionals did so
without including a question. A majority of patients
and parents who did not ask a question completed
other parts of the survey form, whereas healthcare
professionals and researchers who did not include a
question left the entire form blank. Usable submis-
sions containing one or more uncertainties were
received from 1636 patients or family members and
652 professionals. Following rewording and reﬁning,
there were 8276 questions. After removing those that
were out of scope (ie, relating to diagnosis, pathogen-
esis, genetic predisposition, new drug development or
access to treatment), not answerable by research,
already answered or not about acne, a total of 6255
questions remained.
Few respondents submitted questions about speciﬁc
interventions; the exception was oral isotretinoin. In con-
sequence, the Steering Group decided, at a special
face-to-face meeting, not to generate a long list of speciﬁc
uncertainties. To produce a manageable short-list for
voting, it was agreed to sort questions into broad themes
with the speciﬁc aim of including as many of the original
questions as possible within these. Rigorous efforts were
made to avoid bias by collating questions in different ways
and counting the number of questions in each set before
the ﬁnal themes were selected. Additionally, members of
the steering group were asked to review the tentative
groupings and could ask for new themes to be evaluated.
An example of a broad uncertainty with samples of illus-
trative questions included within this theme is given in
online supplementary table S1.
The number of people submitting questions relating
to each theme was calculated separately for respondents
to each version of the survey and compared. The most
common themes are shown in table 1. Over a quarter of
all respondents (27%) and over a third (37%) of respon-
dents to the patient survey asked about the safety and/
or efﬁcacy of physical therapies. This was the interven-
tion type about which most questions were asked. Some
uncertainties were submitted by similar proportions of
patients and professionals, whereas there were marked
differences for others.
The 29 most popular themes were taken forward to the
vote together with an additional uncertainty about the
prevention and management of post-inﬂammatory pig-
mentation, which was identiﬁed by many people with
acne in pigmented skin. Together, the top 30 themes
encompassed more than 87% of the submitted questions.
The question “What are the best ways to support self-
management of acne?” was constructed to reﬂect the
large number of submissions, impossible to count accur-
ately using keywords, that reﬂected people’s struggles to
manage their acne without professional help. Popularity
of a theme in the harvesting survey did not predict popu-
larity in the vote or ranking in the top 10 (see below).
Characteristics of survey respondents
Extensive demographic information was collected to
determine whether a representative sample had been
obtained. Interim analyses showed that women were over-
represented in the patient sample. Keeping the survey
open longer and speciﬁcally targeting men via Twitter
did not improve participation by males with acne. At the
close, the professional sample comprised of 64.2%
women (see online supplementary table S2), and the
patient/family member sample comprised of 83.1%
women (see online supplementary table S3). Among the
professionals, most submissions came from doctors,
nurses and pharmacists, working in primary or secondary
care or in the community, but treatment providers
working outside the NHS were also represented (see
online supplementary table S2). Among respondents to
the patient version were 1125 individuals with acne at the
time of completing the survey, 331 who had acne in the
past as well as 132 family members. The age range was as
expected: 40% of respondents to the patient version were
aged 16–24 years (see online supplementary table S3).
The patient sample was predominantly white (80% vs
87% for the UK in 2011 census) but a good spread of
minority ethnic groups was represented. Almost a quarter
of the patient sample (23%) lived outside the UK com-
pared with 15% of the professional sample. Within the
UK, all but ﬁve postcodes were represented in the sample
of patients and family members with a large number of
responses (33%), as might be expected, from Yorkshire,
where the PSP management team and the local NIHR
research network were based. A majority of professionals
(73%) did not disclose their postcodes.
People who had acne at the time that they completed
the survey were asked to provide information about
sources of professional help to ensure that the sample
composition included individuals seeking advice and/or
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treatment from a variety of sources and not just from
within the NHS. Forty-one per cent were not getting any
professional help, although 88% had sought help in the
past (table 2). The most common source of help was a
general practitioner. Interestingly, 26% of respondents
had seen a beauty therapist in the past and 34% had
sought the advice of a pharmacist. Other sources of pro-
fessional help not shown in table 2 included paediatri-
cians, gynaecologists, nurses, health counsellors and the
British Association of Skin Camouﬂage. A minority of
respondents said they obtained help from family and
friends, the internet and/or social media such as
YouTube (an online video sharing website), or became
their own expert.
The most common source of acne treatment was from
a pharmacy with a prescription (see online supplemen-
tary table S4). At the time of completing the survey, 40%
of people with acne were not using any treatment but
82% had used treatment in the past.
How people heard about the harvesting survey
Respondents were asked to identify how they heard
about the survey, and the answers are shown in table 3.
The commonest mechanism identiﬁed by both patients
and professionals was email. Among the professionals,
many (21%) heard about the survey from a colleague.
Many patients and family members had heard about the
survey via social media (notably Facebook and
YouTube), with several speciﬁcally mentioning a celeb-
rity video. Methods with negligible impact were the
Acne PSP website, Twitter account and the printed
word. Three times as many patients heard about the
survey from the Embarrassing Bodies or Talk Health
web sites than from the PSP’s site. There was some
Table 1 Uncertainties identified by 200 or more respondents to the harvesting survey
Number (%) of related submissions
from
Patients/
family
members Professionals
All
respondents In final top 10
1 Which physical therapies, including lasers and
other light based treatments, are safe and effective
in treating acne?
573 (35) 34 (5) 607 (27) Yes
2 Are cosmetic remedies for spot prone skin as
effective as their makers claim them to be?
439 (27) 8 (1) 447 (20) No
3 Which complementary and alternative therapies
are safe and effective in treating acne?
356 (22) 7 (1) 363 (16) No
4 What is the best treatment for acne scars? 324 (20) 32 (5) 356 (16) Yes
5 What is the best topical product for treating acne? 266 (16) 55 (8) 321 (14) Yes
6 What is the correct way to use antibiotics in acne
to achieve the best outcomes with least risk?
159 (10) 121 (19) 285 (12) Yes
7 What dietary advice should be given to people with
acne?
255 (16) 14 (2) 269 (12) Yes (merged with 9)
8 What should a consultation for acne involve? 169 (10) 63 (10) 236 (10) No
9 Which lifestyle factors influence acne severity the
most?
203 (12) 31 (5) 234 (10) Yes (merged with 7)
10 What is the correct way to use oral isotretinoin in
acne in order to achieve the best outcomes with
least risk?
105 (6) 125 (19) 230 (10) Yes
11 What is the best skin care routine for people with
acne?
186 (11) 21 (3) 209 (9) No
12 Does diet affect who gets acne or how severe it is? 150 (9) 54 (8) 204 (9) No
Table 2 Sources of professional help used by
respondents (n=1125) who had acne when they completed
the harvesting survey
Number (%)*
Source of help
In the
past
When
survey
completed
Pharmacist 381 (34) 78 (7)
GP/family doctor 721 (65) 306 (28)
Dermatologist 503 (45) 249 (23)
Complementary or alternative
therapist
94 (8) 27 (2)
Beauty therapist 283 (26) 62 (6)
Private practitioner 62 (6) 22 (2)
Not sought any help in the past 138 (12) N/A
Not getting any help now N/A 448 (41)
Not disclosed 5 (0.5) 75 (7)
Other 68 (6) 7 (0.6)
*Per cent of respondents. Total exceeds the number of
respondents as many individuals selected more than one option.
GP, general practitioner; N/A, not applicable.
Layton A, et al. BMJ Open 2015;5:e008085. doi:10.1136/bmjopen-2015-008085 5
Open Access
group.bmj.com on September 10, 2015 - Published by http://bmjopen.bmj.com/Downloaded from 
evidence of propagation with several people mentioning
organisations we had not directly targeted.
Ranking exercise
A total of 3084 people took part in the online vote. Of
these, 277 votes were excluded because the respondents
identiﬁed themselves as a researcher or ‘other’. Valid
votes were received from 1573 people with acne, 237
family members and 1012 professionals. Again, males
were under-represented; only 25% of patient voters were
male compared to 35% of professionals. A demographic
analysis of votes is shown in table 4; 44% of voters were
aged between 16 and 34 years. A large majority of voters
(85%) lived in the UK and 81% were white. More than
half the patient voters lived in Yorkshire (53.6%). This
time, 78% of professionals provided a postcode; of
these, 21% practiced in Yorkshire. All but seven post-
codes were represented in the patient sample and all
but 15 in the professional sample. Google Analytics
showed that most people landed directly on the voting
survey without visiting other pages before leaving the
PSP web site.
For several uncertainties, there were marked differ-
ences in weighted ranks between patients and profes-
sionals (ﬁgure 1). For others, there was good agreement,
especially among the less popular questions. Popular
uncertainties with the biggest differences in weighted
scores (patients vs professionals) were about use of oral
isotretinoin (191 vs 693), ways of preventing acne (1006
vs 461) and the use of antibiotics (282 vs 972).
The Steering Group used ranked weighted scores to
decide which uncertainties to take forward to the ﬁnal
workshop. The distribution of scores (ﬁgure 2) showed
a long tail and, with one exception, uncertainties in the
tail were not taken forward. The exception was the
uncertainty about the best way to use oral isotretinoin,
which ranked ﬁfth among professionals but 19th among
patients and family members. This meant a total of 18
uncertainties were considered at the ﬁnal workshop.
Final priority setting workshop
A total of 43 people, including 13 patients, 12 profes-
sionals and 13 observers, attended the ﬁnal workshop.
In the ﬁrst session, three groups comprising equal
numbers of patients, professionals and non-participatory
observers, each with an independent moderator, were
asked to prioritise all 18 uncertainties using a nominal
group technique. The results were collated and dis-
cussed in one combined afternoon session, moderated
by the chairman of the steering group. The ﬁnal top 10
set is shown in box 1. Seven uncertainties were ranked
in the top 10 without alteration. There were three
instances in which two related questions were merged;
all three merged questions were also ranked in the top
10. The top 10 set was announced the following day via
the Acne PSP website, Twitter and several partner web
sites. Subsequently, thank you postcards promoting the
top 10 were disseminated in Harrogate dermatology
clinics, at European and Global Alliance acne meetings
and through a meeting supported by the British
Association of Dermatology. Given the number of more
speciﬁc questions, work is still ongoing to optimise
methods of disseminating these to patients and profes-
sionals. In due course, all veriﬁed uncertainties will be
entered into the UK Database of Uncertainties about
the Effects of Treatment (http://www.library.nhs.uk/
duets/).
DISCUSSION
The top 10 acne research priorities, reached by consen-
sus between patients and professionals, reveal concern
about the paucity of evidence on the relative efﬁcacy
and safety of commonly used treatments, and their place
in both short and long-term management. This evidence
gap may reﬂect the low number of robust,
industry-independent trials of acne therapies but also
that efﬁcacy within RCTs does not reliably predict effect-
iveness or patient satisfaction in the real world. In the
past 5 years, no published acne RCTs have been con-
ducted in whole or in part within the UK. Within the
Cochrane library, there are only two published
Cochrane reviews wholly dedicated to acne therapies,
although there are six ongoing Cochrane reviews that
Table 3 How respondents heard about the harvesting
survey
Number (%)*
Mechanism
Patient
version
Professional
version
Email 294 (18) 249 (38)
YouTube video 280 (17) 1 (0.2)
Facebook or other networking
site
238 (15) 1 (0.2)
Acne PSP web site 55 (3) N/A
Website of a professional
organisation
N/A 79 (12)
Other web site 160 (10) 11 (2)
From a friend or relative 104 (6) 12 (2)
From a doctor/other treatment
provider
112 (7) N/A
From a colleague N/A 136 (21)
Poster/leaflet 86 (5) 16 (2)
Newsletter 71 (4) 10 (2)
Word of mouth 79 (5) 21 (3)
Twitter 76 (5) 14 (2)
Advert in newspaper or
magazine
20 (1) 2 (0.3)
Via a network 6 (0.4) 66 (10)
LinkedIn or other professional
networking site
2 (0.1) 60 (9)
Other 66 (4) 16 (2)
Not disclosed 26 (2) 2 (0.3)
*Per cent of respondents. Total exceeds the number of
respondents as some individuals selected more than one option.
N/A, not applicable; PSP, Priority Setting Partnership.
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will provide new insights into some of the uncertainties
in the top 10, speciﬁcally the efﬁcacy and/or safety
of oral isotretinoin, light therapies and topical treat-
ments. Identifying the top 10 priorities of patients and
healthcare professionals highlights the need for more
pragmatic trials that put widely used interventions
head-to-head, and also more focused research to iden-
tify the safest and most effective alternatives to drug
based therapies. While awareness of these alternatives
among patient responders was high, so was scepticism
about paying for such treatments from unregulated
practitioners outside the NHS. Several uncertainties
that were very frequently identiﬁed by respondents to
the harvesting survey, including two of the three most
asked about intervention types (complementary and
alternative medicines (CAM), cosmetic remedies), did
not make it into the top 10. Although there was clearly
a lot of interest in them among people with acne, they
did not rank in most voters’ top 3 when presented
alongside the other shortlisted questions.
Among submissions to the harvesting survey, we
received many treatment-related questions not answer-
able by research and so not included in the
prioritisation exercise. They asked about such things as
availability of non-drug based treatments within the
NHS, and how to identify reliable sources of advice
about their safety and efﬁcacy. There were also many
questions about affordability and accessibility of treat-
ments not provided by the NHS. These questions
reﬂected valid concerns among people with acne and
should be addressed by information providers, policy-
makers and regulatory bodies.
Almost half the people who submitted the harvesting
survey did not include a question, although most
patients and parents did provide demographic informa-
tion and contact details. This may reﬂect the offer of a
small ﬁnancial inducement even though the survey form
clearly speciﬁed that inclusion in the prize draw was
dependent on submitting at least one question.
Feedback from local patients indicated that they were
deﬁnitely interested in the survey (sufﬁcient to want to
open it) and curious about its content. The issue was
that they had nothing speciﬁc they wanted to ask or did
not know how to frame a research question. It remains
unclear why 302 professionals and 30 researchers did
not submit a question.
Table 4 Demographic analysis of the vote
Number (% within group)
Health care
professionals People with acne*
Parents, guardians
or partners All groups
n 1012 1573 237 2822
Gender
Male 356 (35) 400 (25) 58 (24) 814 (29)
Female 647 (64) 1157 (74) 175 (74) 1979 (70)
Not disclosed 9 (0.9) 16 (1) 4 (2) 29 (1)
Age range
≤15 years 0 72 (5) 1 (0.4) 73 (3)
16–24 years 34 (3) 633 (40) 11 (5) 678 (24)
25–34 years 164 (16) 443 (28) 7 (3) 614 (22)
35–44 years 258 (25) 229 (15) 37 (16) 524 (19)
45–54 years 307 (30) 128 (8) 122 (52) 557 (20)
55–64 years 198 (20) 51 (3) 42 (18) 291 (10)
65 years and over 39 (4) 16 (1) 11 (5) 66 (2)
Not disclosed 12 (1) 1 (0.1) 6 (3) 19 (0.7)
Location
UK 846 (84) 1337 (85) 221 (93) 2404 (85)
Overseas 166 (16) 236 (15) 16 (7) 418 (15)
Ethnicity
Asian Bangladeshi 1 9 0 10
Asian Chinese 16 11 1 28
Asian Indian 58 54 5 117
Asian Pakistani 19 61 16 96
Black African 10 16 2 28
Black Caribbean 7 14 1 22
Hispanic 9 24 2 35
Mixed race 14 53 1 68
White 817 (81) 1268 (81) 204 (86) 2289 (81)
Other 39 40 2 81
Not disclosed 22 23 3 48
*1162 individuals had acne when they voted; 411 had acne in the past.
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At the time the Acne PSP was set-up, the JLA process
of priority setting through partnership and consensus
had already become established. Several PSPs have
revised the basic procedures laid down in the JLA guide-
book and adopted new strategies to overcome difﬁculties
associated with speciﬁc diseases or hard-to-reach groups.
For example, the stroke PSP devised a new model for
assisted participation and targeted engagement of stroke
survivors with communication difﬁculties.21 No previous
priority setting exercise has been completed for a very
common condition that primarily affects teenagers and
young adults. We recognised that they might be hard to
engage and motivate in an exercise such as this. There
are at least three million people with acne in the UK at
any one time. A sample of 0.05% would represent a
minimum of 1500 people. While this sounds easily
achievable, in fact it was extremely challenging. A huge
amount of work by large numbers of people went on
behind the scenes to achieve this. Initial discussions with
young people suggested that it would be necessary to
break with JLA tradition in several ways, including: a very
different layout for the harvesting survey, the use of a
small ﬁnancial inducement and emphasis on the use of
social media to promote participation. Whether due to
the layout of the harvesting survey or not, we obtained a
much broader range of uncertainties from patients than
from professionals, almost certainly as a consequence of
reminding people what treatments are available. Perhaps
as a result of opening people’s eyes to treatments they
were not aware of, we also received many questions from
patients about therapies not available within the NHS,
most commonly physical treatments as well as CAM.
In contrast, two types of drug treatment dominated
questions from professionals: antibiotics and oral isotreti-
noin. Among numerous questions relating to the
conduct of a consultation for acne, many asked about
doctors’ reluctance to engage in conversations about
alternatives to commonly used drug-based therapies.
Feedback from respondents showed that some promo-
tional activities were much more successful than others
and this information may be of use to those conducting
PSPs in future. It was almost certainly not necessary to
have a dedicated PSP website or Twitter account and lea-
ﬂeting via a national chain of pharmacies was not as suc-
cessful as we had hoped. The role of partner
organisations was vital in publicising the PSP and
encouraging participation. With such a prevalent condi-
tion, we felt it was necessary to demonstrate that respon-
dents to the harvesting survey and vote were
representative of all people with acne and all profes-
sionals who offer care.
The demographic information we collected showed a
pronounced local concentration of survey respondents
in Yorkshire, where both the PSP management team
and local NIHR network, which helped to promote the
survey, are based. While the effort: reward ratio, in terms
of respondent numbers to hours spent on promoting
the survey, might be low, it guaranteed that we achieved
a representative sample in terms of age, location and
ethnic mix. With patient gender, we were not so success-
ful. Ours is not the ﬁrst or only PSP to ﬁnd that only a
minority of respondents were male,3 22 23 although
many PSPs do not report the gender of participants. It is
Figure 1 Flow diagram showing the number of participants
and submissions at each stage.
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perhaps particularly surprising for acne, as there are
fewer treatment options for men. The smaller gender
bias among healthcare professionals is not of concern as
it simply reﬂects the 60:40 ratio of females to males
within dermatology, pharmacy and general practice in
the UK. Weighted ranks show that uncertainties voted
for by men and women were broadly similar with the
exception of a question about managing acne in mature
women (data not shown). This suggests that gender bias
in the sample may not have affected the ﬁndings of the
PSP to a signiﬁcant extent. However, we perhaps could
have made greater attempts to target males, for
example, via sports clubs, magazines, men’s lifestyle web-
sites or schools for boys.
Because of the large number of questions submitted,
our approach, as in several PSPs before us, was to merge
very speciﬁc questions on related themes into broad
questions that could be voted on. Any PSP has to
balance the sample size required to reach saturation (ie,
few or no new uncertainties identiﬁed by increasing par-
ticipation) with the practicalities of processing the large
volumes of data generated. The novel use of key words
based on MeSH descriptors in this PSP was essential to
facilitate sorting and grouping. Following the PSP,
preliminary discussions have been held with National
Institute for Health Research (NIHR) Evaluation Trials
and Studies Co-ordinating Centre (NETSCC) about
translating the top 10 uncertainties into researchable
questions that faithfully represent the original submis-
sions. A forthcoming challenge is to capture and dissem-
inate, via UK DUETs and other mechanisms, the
insightful and more detailed questions that have been
lost as a result of merging.
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from patients, partners and other family members are shown in blue; summed weighted scores from professionals are shown in
orange.
Box 1 The top 10 research priorities for the treatment of acne
1. What management strategy should be adopted for the treat-
ment of acne in order to optimise short and long-term
outcomes?
2. What is the correct way to use antibiotics in acne to achieve
the best outcomes with least risk?
3. What is the best treatment for acne scars?
4. What is the best way of preventing acne?
5. What is the correct way to use oral isotretinoin (Roaccutane) in
acne in order to achieve the best outcomes with least risk of
potentially serious adverse effects?
6. Which lifestyle factors affect acne susceptibility or acne severity
the most and could diet be one of them?
7. What is the best way of managing acne in mature women who
may/may not have underlying hormonal abnormalities?
8. What is the best topical product for treating acne?
9. Which physical therapies, including lasers and other light
based treatments, are safe and effective in treating acne?
10. How long do acne treatments take to work and which ones
are fastest acting?
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